AI Article Synopsis
- * Since the original KDIGO HCV Guideline was released in 2008, new antiviral treatments have emerged that make it possible to cure HCV in CKD patients.
- * The Work Group reviewed and updated the KDIGO HCV in CKD Guideline, focusing on modern diagnostic methods and treatment options, as highlighted in the Executive Summary.
Article Abstract
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.kint.2018.06.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!